Literature DB >> 20053373

Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice.

Eva Machová1, Vladimír Rudajev, Helena Smycková, Henna Koivisto, Heikki Tanila, Vladimír Dolezal.   

Abstract

We investigated the functional characteristics of pre- and postsynaptic cholinergic transmission in APPswe/PS1dE9 double transgenic mice at a young age (7-10 weeks) before the onset of amyloid plaque formation and at adult age (5-6 months) at its onset. We compared brain slices from cerebral cortex and hippocampus with amyloid deposits to slices from striatum with no amyloid plaques by 6 months of age. In young transgenic mice we found no impairments of preformed and newly synthesized [(3)H]-ACh release, indicating intact releasing machinery and release turnover, respectively. Adult transgenic mice displayed a significant increase in preformed [(3)H]-ACh release in cortex but a decrease in hippocampus and striatum. The extent of presynaptic muscarinic autoregulation was unchanged. Evoked release of newly synthesized [(3)H]-ACh was significantly reduced in the cortex and hippocampus but unchanged in the striatum. Carbachol-induced G-protein activation in cortical membranes displayed decreased potency but normal efficacy in adult animals and no changes in young animals. These results indicate that functional pre- and postsynaptic cholinergic deficits are not present in APPswe/PS1dE9 transgenic mice before 10 weeks of age, but develop along with beta-amyloid accumulation in the brain. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053373     DOI: 10.1016/j.nbd.2009.12.023

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  18 in total

1.  Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.

Authors:  Stephanie L Adams; Laurent Benayoun; Kathy Tilton; Tiffany J Mellott; Sudha Seshadri; Jan Krzysztof Blusztajn; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

3.  Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.

Authors:  David Cheng; Jac Kee Low; Warren Logge; Brett Garner; Tim Karl
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

4.  Metabolomic and lipidomic changes triggered by lipopolysaccharide-induced systemic inflammation in transgenic APdE9 mice.

Authors:  Elena Puris; Štěpán Kouřil; Lukáš Najdekr; Sanna Loppi; Paula Korhonen; Katja M Kanninen; Tarja Malm; Jari Koistinaho; David Friedecký; Mikko Gynther
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

5.  Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.

Authors:  Tarja Malm; Jari Koistinaho; Katja Kanninen
Journal:  Int J Alzheimers Dis       Date:  2011-10-30

6.  Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model.

Authors:  Aaron N Long; Katrina Owens; Anna E Schlappal; Tibor Kristian; Paul S Fishman; Rosemary A Schuh
Journal:  BMC Neurol       Date:  2015-03-01       Impact factor: 2.474

Review 7.  Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases.

Authors:  Andrzej Szutowicz; Hanna Bielarczyk; Agnieszka Jankowska-Kulawy; Tadeusz Pawełczyk; Anna Ronowska
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

8.  A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice.

Authors:  Diane Jansen; Valerio Zerbi; Carola I F Janssen; Pieter J W C Dederen; Martina P C Mutsaers; Anne Hafkemeijer; Anna-Lena Janssen; Cindy L M Nobelen; Andor Veltien; Jack J Asten; Arend Heerschap; Amanda J Kiliaan
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Mitochondrial oxygen consumption deficits in skeletal muscle isolated from an Alzheimer's disease-relevant murine model.

Authors:  Rosemary A Schuh; Kathryn C Jackson; Anna E Schlappal; Espen E Spangenburg; Christopher W Ward; Ji H Park; Natalie Dugger; Guo Li Shi; Paul S Fishman
Journal:  BMC Neurosci       Date:  2014-02-13       Impact factor: 3.288

10.  IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.

Authors:  Tiffany J Mellott; Sarah M Pender; Rebecca M Burke; Erika A Langley; Jan Krzysztof Blusztajn
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.